{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:51:47Z","timestamp":1768567907642,"version":"3.49.0"},"posted":{"date-parts":[[2025,6,18]]},"group-title":"Urology","reference-count":23,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction and Objectives<\/jats:title>\n                  <jats:p>Many women with multiple sclerosis (MS) experience neurogenic overactive bladder (NOAB) characterized by urinary frequency, urinary urgency and urgency incontinence. The objective of the study was to create machine learning (ML) models utilizing clinical and imaging data to predict NOAB treatment success stratified by treatment type.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective cohort study of female patients with diagnosis of NOAB and MS seen at a tertiary academic center from 2017-2022. Clinical and imaging data were extracted. Three types of NOAB treatment options evaluated included behavioral therapy, medication therapy and minimally invasive therapies. The primary outcome \u2013 treatment success was defined as &gt; 50% reduction in urinary frequency, urinary urgency or a subjective perception of treatment success. For the construction of the logistic regression ML models, bivariate analyses were performed with backward selection of variables with p-values of &lt; 0.10 and clinically relevant variables applied. For ML, the cohort was split into a training dataset (70%) and a test dataset (30%). Area under the curve (AUC) scores are calculated to evaluate model performance.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The 110 patients included had a mean age of patients were 59 years old (SD 14 years), with a predominantly White cohort (91.8%), post-menopausal (68.2%). Patients were stratified by NOAB treatment therapy type received with 70 patients (63.6%) at behavioral therapy, 58 (52.7%) with medication therapy and 44 (40%) with minimally invasive therapies. On MRI brain imaging, 63.6% of patients had &gt; 20 lesions though majority were not active lesions. The lesions were mostly located within the supratentorial (94.5%), infratentorial (68.2%) and 58.2 infratentorial brain (63.8%) as well as in the deep white matter (53.4%). For MRI spine imaging, most of the lesions were in the cervical spine (71.8%) followed by thoracic spine (43.7%) and lumbar spine (6.4%).10.3%). After feature selection, the top 10 highest ranking features were used to train complimentary LASSO-regularized logistic regression (LR) and extreme gradient-boosted tree (XGB) models. The top-performing LR models for predicting response to behavioral, medication, and minimally invasive therapies yielded AUC values of 0.74, 0.76, and 0.83, respectively.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Using these top-ranked features, LR models achieved AUC values of 0.74-0.83 for prediction of treatment success based on individual factors. Further prospective evaluation is needed to better characterize and validate these identified associations.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.06.17.25329802","type":"posted-content","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T01:00:17Z","timestamp":1750294817000},"source":"Crossref","is-referenced-by-count":0,"title":["USING ARTIFICIAL INTELLIGENCE TO PREDICT TREATMENT OUTCOMES IN PATIENTS WITH NEUROGENIC OVERACTIVE BLADDER AND MULTIPLE SCLEROSIS"],"prefix":"10.64898","author":[{"given":"Oliva H.","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaylen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Demetriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025062016351574000_2025.06.17.25329802v1.1","unstructured":"Rivera VM . Multiple Sclerosis: Diagnosis and Treatment. ( Rivera V , ed.). MDPI -Multidisciplinary Digital Publishing Institute; 2022."},{"issue":"5","key":"2025062016351574000_2025.06.17.25329802v1.2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrurol.2016.53","article-title":"Management of neurogenic bladder in patients with multiple sclerosis","volume":"13","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"4","key":"2025062016351574000_2025.06.17.25329802v1.3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.juro.2009.12.029","article-title":"Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry","volume":"183","year":"2010","journal-title":"J Urol"},{"issue":"5","key":"2025062016351574000_2025.06.17.25329802v1.4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/JU.0000000000002235","article-title":"The AUA\/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation","volume":"206","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"2025062016351574000_2025.06.17.25329802v1.5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/nau.22670","article-title":"The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis","volume":"35","year":"2016","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"2025062016351574000_2025.06.17.25329802v1.6","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/nau.24936","article-title":"Barriers and facilitators to overactive bladder therapy adherence","volume":"41","year":"2022","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"2025062016351574000_2025.06.17.25329802v1.7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The AUA\/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder","volume":"212","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"2025062016351574000_2025.06.17.25329802v1.8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12911-023-02238-9","article-title":"XGBoost-SHAP-based interpretable diagnostic framework for alzheimer\u2019s disease","volume":"23","year":"2023","journal-title":"BMC Med Inform Decis Mak"},{"key":"2025062016351574000_2025.06.17.25329802v1.9","unstructured":"The R Project for Statistical Computing. https:\/\/www.r-project.org\/."},{"key":"2025062016351574000_2025.06.17.25329802v1.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9868.2005.00503.x"},{"key":"2025062016351574000_2025.06.17.25329802v1.11","first-page":"785","volume-title":"In: Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining","volume":"13-","year":"2016"},{"key":"2025062016351574000_2025.06.17.25329802v1.12","doi-asserted-by":"crossref","unstructured":"Liu Y , Just A. SHAPforxgboost: SHAP Plots for \u201cXGBoost.\u201d CRAN: Contributed Packages. August 2019.","DOI":"10.32614\/CRAN.package.SHAPforxgboost"},{"key":"2025062016351574000_2025.06.17.25329802v1.13","doi-asserted-by":"crossref","unstructured":"Ganz ML , Smalarz AM , Krupski TL , et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3).","DOI":"10.1016\/j.urology.2009.08.003"},{"key":"2025062016351574000_2025.06.17.25329802v1.14","doi-asserted-by":"crossref","unstructured":"Werneburg GT , Werneburg EA , Goldman HB , Slopnick E , Roberts LH , Vasavada SP . External validation demonstrates machine learning models outperform human experts in prediction of objective and patient-reported overactive bladder treatment outcomes. Urology. December 2024.","DOI":"10.1016\/j.urology.2024.08.071"},{"key":"2025062016351574000_2025.06.17.25329802v1.15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/nau.24881","article-title":"Machine learning provides an accurate prognostication model for refractory overactive bladder treatment response and is noninferior to human experts","volume":"41","year":"2022","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"2025062016351574000_2025.06.17.25329802v1.16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/nau.25075","article-title":"Disruption of specific white matter tracts is associated with neurogenic lower urinary tract dysfunction in women with multiple sclerosis","volume":"42","year":"2023","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"2025062016351574000_2025.06.17.25329802v1.17","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1097\/SPV.0000000000000830","article-title":"Are White Matter Tract Integrities Different in Multiple Sclerosis Women With Voiding Dysfunction?","volume":"27","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"2","key":"2025062016351574000_2025.06.17.25329802v1.18","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.juro.2016.09.077","article-title":"Functional Magnetic Resonance Imaging with Concurrent Urodynamic Testing Identifies Brain Structures Involved in Micturition Cycle in Patients with Multiple Sclerosis","volume":"197","year":"2017","journal-title":"J Urol"},{"issue":"3","key":"2025062016351574000_2025.06.17.25329802v1.19","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/nau.24304","article-title":"Brain activation patterns of female multiple sclerosis patients with voiding dysfunction","volume":"39","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"2025062016351574000_2025.06.17.25329802v1.20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00192-022-05300-8","article-title":"The effect of oral medications on fMRI brain activation: A randomized, double blind, controlled pilot trial of older women with overactive bladder","volume":"34","year":"2023","journal-title":"Int Urogynecol J"},{"key":"2025062016351574000_2025.06.17.25329802v1.21","doi-asserted-by":"crossref","unstructured":"Funada S , Yoshioka T , Luo Y , Sato A , Akamatsu S , Watanabe N. Bladder training for treating overactive bladder in adults. Cochrane Database of Systematic Reviews. 2023;2023(10).","DOI":"10.1002\/14651858.CD013571.pub2"},{"issue":"8","key":"2025062016351574000_2025.06.17.25329802v1.22","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study","volume":"179","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025062016351574000_2025.06.17.25329802v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30277-5"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.06.17.25329802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:38:42Z","timestamp":1768509522000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.06.17.25329802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1101\/2025.06.17.25329802","relation":{},"subject":[],"published":{"date-parts":[[2025,6,18]]},"subtype":"preprint"}}